

September 28, 2007
Kissei Pharmaceutical Co., Ltd.
Eisai Co., Ltd.

Kissei and Eisai sign a license agreement to develop and commercialize *Glufast*[®],
a rapid-acting insulin secretagogue in China

Kissei Pharmaceutical Co., Ltd. (Headquarters: Matsumoto City, Nagano, President & CEO: Mutsuo Kanzawa; hereinafter referred to as “Kissei”) and Eisai Co., Ltd. (Headquarters: Bunkyo Ward, Tokyo, President & CEO: Haruo Naito; hereinafter referred to as “Eisai”) announced the conclusion of a license agreement for *Glufast*[®] (tablets, generic name: mitiglinide calcium hydrate), a rapid-acting insulin secretagogue originally created by Kissei. In this agreement, Eisai gained the exclusive development and commercialization rights of *Glufast*[®] in China from Kissei.

Kissei is now conducting Phase III clinical trial for *Glufast*[®] in China. Eisai will market *Glufast*[®] in China after Kissei has been granted im